Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Tactics of Antiarrhythmic Therapy in Comorbid Elderly and Senile Patients with Paroxysmal and Recurrent Atrial Fibrillation

https://doi.org/10.20996/1819-6446-2018-14-5-670-677

Full Text:

Abstract

Aim. Comparison of different treatment tactics – medicated antiarrhythmic therapy (AAT) and radiofrequency ablation (RFA) of elderly and senile pa- tients with relapsing atrial fibrillation (AF) as more severe patients with a burdened comorbid background.

Material  and  methods. The study  included  108 patients  with  paroxysmal  and  persistent  AF who  were  in  hospital  and  then  under  outpatient observation for 2 years. Depending on the method of treatment, patients were divided into 2 groups: the group receiving medicated AAT (n=45) and the group  treated with RFA (63 patients). Most patients of the 2nd  group  (n=60) after  the RFA received AAT, i.e. so-called hybrid therapy. These groups  were comparable in age (mean age 64.9 and 64.7 years, respectively), sex and underlying pathology, comorbid diseases.

Results. In patients who received "hybrid" therapy after 2 years of observation, it was more often possible to preserve  the sinus rhythm and achieve a reduction in arrhythmia episodes in comparison with the  drug  group  (95.2% and  86.6%, respectively). Quality of life and  the  frequency of complications of AAT in these groups  of patients were comparable.

Conclusion: In elderly and senile patients with paroxysmal and persistent atrial fibrillation, RFA and hybrid therapy was more effective for maintaining sinus rhythm compared to drug therapy. After RFA in this category of patients, in most cases, medicated AAT was used. When choosing the tactics of rational AAT in elderly patients, preference should be given to tactics in which it is possible to achieve an improvement in the quality of life.

About the Authors

M. H. Fedorova
Central State Medical Academy of Administrative Department of the President of the Russian Federation
Russian Federation

Fedorova (Ilyina) Marianna Khasanovna – MD, Post-Graduate Student, Chair of Therapy and Cardiology, Central State Medical Academy of Administrative Department of the President of the Russian Federation.

Marshala Timoshenko ul. 19-1A, Moscow, 121359.

 



V. L. Doshchitsin
Central State Medical Academy of Administrative Department of the President of the Russian Federation
Russian Federation

Vladimir  L. Doshchitsin – MD, PhD, Professor, Chair of Therapy and Cardiology, Central State Medical Academy of Administrative Department of the President of the Russian Federation.

Marshala Timoshenko ul. 19-1A, Moscow, 121359.

 



A. V. Chapurnykh
Central Clinical Hospital and Polyclinic of Administrative Department of the President of the Russian Federation
Russian Federation

Alexander V. Chapurnykh – MD, PhD, Professor, Head of Surgical Department, Central Clinical Hospital and Polyclinic of Administrative Department of the President of the Russian Federation.

Marshala Timoshenko ul. 15,  Moscow, 121359.

 



References

1. Benjamin E.J., Levy D., Vaziri S.M. et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271(11):840-4. doi:10.1001/jama.1994.03510350050036.

2. Golzari H., Cebul R.D., Bahler R.C. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med. 1996;125(4):311-23. doi:10.7326/0003-4819-125-4-199608150-00010.

3. Corrado A., Patel D., Riedlbauchova L. et al. Efficacy, safety, and outcome of atrial fibrillation ablation in septuagenarians. Cardiovasc Electrophysiol 2008;19(8):807-11. doi:10.1111/j.1540-8167.2008.01124.x.

4. Wazni O.M., Marrouche N.F., Martin D.O., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005;293(21):2634-40. doi:10.1001/jama.293.21.2634.

5. Zado E., Callans D., Riley M., et al. Long-Term Clinical Efficacy and Risk of Catheter Ablation for Atrial Fibrillation in the Elderly. Cardiovascular Electrophysiol. 2008;19(6):621-6. doi:10.1111/j.1540-8167.2008.01183.x.

6. Haegeli M., Duru F., Lockwood E., et al. Ablation of atrial fibrillation after the retirement age: considerations on safety and outcome. Journal of Interventional Cardiac Electrophysiology. 2010;28(3):193-7. doi:10.1007/s10840-010-9490-8.

7. Bunch T.J., Weiss J.P., Crandall B.G., et al. Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians. Pace-Pacing and Clinical Electrophysiology. 2010;33(2):146-52. doi:10.1111/j.1540-8159.2009.02604.x.

8. Tan H.W., Wang X.H., Shi H.F., et al. Efficacy, safety and outcome of catheter ablation for atrial fibrillation in octogenarians. International Journal of Cardiology. 2010;145(1):147-8. doi:10.1016/j.ij-card.2009.06.055.

9. Nademanee K., Amnueypol M., Lee F., et al. Benefits and risks of catheter ablation in elderly patients with atrial fibrillation. Heart Rhythm. 2015;12(1):44-51. doi:10.1016/j.hrthm.2014.09.049.

10. Lim T., Day J., Weiss P., Crandall B., et al. More Aggressive Left Atrial Ablation in Elderly Patients does not Increase Procedural Complications and Favorably Impacts Outcomes. J of Innovations in Cardiac Rhythm Management. 2011;2:206-11.

11. Lioni L., Letsas K.P., Efremidiset M., et al. Catheter ablation of atrial fibrillation in the elderly. J Geriatr Cardiol. 2014;11(4):291-5. doi:10.11909/j.issn.1671-5411.2014.04.003.

12. Oral H., Knight B.P., Ozaydin M., et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol. 2002;40(1):100-4. doi:10.1016/S0735-1097(02)01939-3.

13. Choi J.I., Pak H.N., Park J.S. et al. Clinical significance of early recurrences of atrial tachycardia after atrial fibrillation ablation. Cardiovasc Electrophysiol. 2010;21(12):1331-7. doi:10.1111/j.1540-8167.2010.01831.x.

14. Cappato R., Calkins H., Chen S.A., et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(1):32-8. doi:10.1161/CIRCEP.109.859116.

15. Leong-Sit P., Roux J.F., Zado E., et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. Circ Arrhythm Electrophysiol. 2011;4(1):11-4. doi:10.1161/CIRCEP.110.955393.

16. Salghetti F., Vizzardi E., Elmaghawry M., et al. Need for Ongoing Anti Arrhythmic Drugs After Ablation of Atrial Fibrillation. Rev Recent Patents on Cardiovascular Drug Discovery. 2013;8:204-15.

17. Ware J.Е., Snow К.К., Kosinski М., et al. Sf-36 Health Survey. Manuel and Interpretation Guide, Lincoln, RI: Quality Metric Incorporated; 2000.

18. Andrade J.G., Khairy P., Verma A., et al. Early recurrence of atrial tachyarrhythmias following radiofrequency catheter ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2012;35(1):106-16. doi:10.1111/j.1540-8159.2011.03256.x.

19. Themistoclakis S., Schweikert R.A., Saliba W.I., et al. Clinical predictors and relationship between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation. Heart Rhythm. 2008;5(5):679-85. doi:10.1016/j.hrthm.2008.01.031.

20. National guidelines for the diagnosis and treatment of atrial fibrillation (2012). Russian Cardiology Journal. 2013;4:1-21. (In Russ.).

21. Paulus K., Stefano B., Dipak K., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 7;37(38):2893-962. doi:10.1093/eurheartj/ehw210.

22. Van Gelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-40. doi:10.1056/NEJMoa021375.

23. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl Med. 2008;358:2667-77. doi:10.1056/NEJMoa0708789.

24. Nikolaos K., Konstantinos P.L., Konstantinos V., et al. Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vasc Health Risk Manag. 2015;11:555-62. doi:10.2147/VHRM.S83664.

25. Craig T., January L., Samuel W., et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 2;130(23):e199-267. doi:10.1161/CIR.0000000000000041.

26. Epstein A.E., Bigger J.T., Wyse D.S., et al. Events in the Cardiac Arrhythmia Suppression Trial (CAST): Mortality in the entire population enrolled. J Am Coll Cardiol. 1991;18:14-9. doi:10.1016/S0735-1097(10)80210-4.

27. Greene H.L., Roden D.M., Katz R.J., et al. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. J Am Coll Cardiol. 1992;19(5):894-8. doi:10.1016/0735-1097(92)90267-Q.

28. Blagova O.B., Gilyarov M.J., Nedostup A.V., et al. The use of antiarrhythmic drugs I class in patients with organic damage to the heart. In: Sulimov VA, ed. Medicamental treatment of heart rhythm disturbances. Moscow: GEOTAR-Media; 2011. p. 409-16. (In Russ.).

29. Doschitsin V.L. The controversial issue of drug therapy is cardiac arrhythmias. Kremlevskaya meditsina. Klinicheskiy Vestnik. 2015;3:147-50. (In Russ.).

30. Oganov R.G., Denisov I.N., Simanenkov V.I., et al. All-Russian Public Organization Association of General Practitioners (Family Physicians). Comorbid pathology in clinical practice. Clinical guidelines. Cardiovascular Therapy and Prevention. 2017;16(6):5-56. (In Russ.).


For citation:


Fedorova M.H., Doshchitsin V.L., Chapurnykh A.V. Tactics of Antiarrhythmic Therapy in Comorbid Elderly and Senile Patients with Paroxysmal and Recurrent Atrial Fibrillation. Rational Pharmacotherapy in Cardiology. 2018;14(5):670-677. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-5-670-677

Views: 324


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)